US approval for bleeding disorder drug

(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) 'VONVENDI,' the new drug from Baxalta Incorporated, has just been approved by the United States Food and Drug Administration. It is the first, and so far the only, recombinant protein for the treatment of von Willebrand disease, and offers those affected a new therapeutic option for the first time in more than 10 years.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news